aTyr Pharma Inc.’s recent filing unveils that its President and CEO Shukla Sanjay acquired Company’s shares for reported $30224.0 on Jul 28. In the deal valued at $2.01 per share,15,000 shares were bought. As a result of this transaction, Shukla Sanjay now holds 76,173 shares worth roughly $ 0.13 million.
Then, SCHIMMEL PAUL bought 200,000 shares, generating $450,000 in total proceeds. Upon buying the shares at $2.25, the Director now owns 313,023 shares.
Before that, Broadfoot Jill Marie sold 1,566 shares. aTyr Pharma Inc. shares valued at $3,696 were divested by the Chief Financial Officer at a price of $2.36 per share. As a result of the transaction, Broadfoot Jill Marie now holds 15,460 shares, worth roughly $26282.0.
Oppenheimer downgraded its aTyr Pharma Inc. [LIFE] rating to a Perform from a an Outperform in a research note published on Friday.
Price Performance Review of LIFE
On Friday, aTyr Pharma Inc. [NASDAQ:LIFE] saw its stock remained unchanged to $1.70. On the same session, the stock had its day’s lowest price of $1.70, but rose to a high of $1.74. Over the last five days, the stock has lost -8.11%. aTyr Pharma Inc. shares have fallen nearly -22.37% since the year began. Nevertheless, the stocks have fallen -50.29% over the past one year. While a 52-week high of $3.75 was reached on 05/15/23, a 52-week low of $1.55 was recorded on 04/21/23. SMA at 50 days reached $1.9660, while 200 days put it at $2.1309. A total of 0.19 million shares were traded, compared to the trading of 0.38 million shares in the previous session.
Levels Of Support And Resistance For LIFE Stock
The 24-hour chart illustrates a support level at 1.6867, which if violated will result in even more drops to 1.6733. On the upside, there is a resistance level at 1.7267. A further resistance level may holdings at 1.7533. The Relative Strength Index (RSI) on the 14-day chart is 25.46, which indicates oversold technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -0.1124, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 87.50%. Stochastics %K at 9.59% indicates the stock is a buying.
How much short interest is there in aTyr Pharma Inc.?
A steep rise in short interest was recorded in aTyr Pharma Inc. stocks on Aug 14, 2023, dropping by 57600.0 shares to a total of 0.41 million shares. Yahoo Finance data shows the prior-month short interest on Jul 13, 2023 was 0.47 million shares. There was a decline of -13.91%, which implies that there is a negative sentiment for the stock. In spite of short shares comprising just 1.08% of the overall stock float, the days-to-cover ratio (short ratio) fell to 1.36.
aTyr Pharma Inc. [LIFE] – Who Are The Largest Shareholders?
In filings from Federated Global Investment Manag, it is revealed that the company now owns 10,189,966 shares, or roughly 18.77% of the outstanding LIFE shares. Additionally, Fidelity Management & Research Co increased 2.13% of its stake after which the total value it holdings stand at $15,961,775, while Stonepine Capital Management LLC reduced -4.11% of its stake to hold $9.07 million in the firm. At present, Alyeska Investment Group LP is holding 2,205,555 shares valued at $4.32 million. BlackRock Fund Advisors owned 1,360,232 shares of the company at the time of its most recent 13F filing, worth $2.67 million.
According to FactSet, aTyr Pharma Inc.’s share price will average $23.20 in the next year, based on opinions of analysts polled by the firm. This is up nearly 1076.47 percent from its previous closing price of $1.70. Analysts expect aTyr Pharma Inc. stock to reach the higher price of $35.00, while the lowest price estimate is $12.00. However, 6 analysts have rated LIFE stock as a Buy in their predictions for 2023.